Abstract 446P
Background
Recently updated results of clinical trials have confirmed that palbociclib, ribociclib and abemaciclib plus letrozole/anastrozole significantly prolonged survival compared to placebo plus letrozole/anastrozole in the first-line treatment for postmenopausal women with HR+/HER2- metastatic breast cancer. However, the high cost of CDK4/6 inhibitors imposes a huge financial burden on patients and healthcare systems.
Methods
Studies estimating CDK4/6 inhibitors plus NSAI for HR+/HER2- ABC were searched. A network meta-analysis was made with the main outcomes HRs of OS and PFS. The costs and efficacy of four first-line therapies for HR+/HER2- ABC were evaluated by Markov model. The main outcomes in the cost-effectiveness analysis were incremental cost-utility ratios (ICURs), incremental monetary benefit (INMB), and incremental net-health benefit (INHB). The robustness of the model was assessed by one-way, three-way, and probabilistic sensitivity analyses.
Results
Seven studies involving 5347 patients were included in the NMA. The three first-line CDK4/6 inhibitors plus NSAI groups provided significant PFS and OS superiority to NSAI alone. Abem+NSAI represented a significant statistical advantage on PFS and indicated a trend in best OS benefit compared to the Placebo+NSAI group. Abem+NSAI, Palbo+NSAI, and Ribo+NSAI groups resulted in additional costs of $12,602, $20,391, and $81,258, with additional effects of 0.38, 0.31, and 0.30 QALYs, respectively, leading to an ICUR of $33,163/QALY, $65,777/QALY, and $270,860/QALY. Additional pairwise comparisons showed Abem+NSAI was the only cost-effective option in three CDK4/6 inhibitors plus NSAI groups. The sensitivity analyses showed that the proportion of receiving subsequent CDK4/6 inhibitors and the cost of abemaciclib significantly influenced the results of Abem+NSAI.
Conclusions
From the Chinese payers'perspective, Abem+NSAI was a cost-effective treatment compared with Placebo+NSAI at the willingness-to-pay of $38,029/QALY. The Palbo+NSAI and Ribo+NSAI groups were cost-effective unless adjusting drug prices to 50% or 10% of current prices is probably cost-effective.
Clinical trial identification
CRD42023399342.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1288P - Neoadjuvant therapy with anti-PD-1/PD-L1 plus platinum-base chemotherapy for resectable stage II-III non-small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials
Presenter: Maria Dacoregio
Session: Poster session 04
1289TiP - LANTERN study: A multi-omics digital human avatar for integrating precision medicine into clinical practice for lung cancer patients
Presenter: Emilio Bria
Session: Poster session 04
1294P - A final analysis of a phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage III non–small-cell lung cancer: TORG1937 (DATE study)
Presenter: Tetsuro Kondo
Session: Poster session 04
1296P - Neoadjuvant camrelizumab and apatinib in patients with resectable non-small-cell lung cancer: One-year update from a phase II trial
Presenter: Wei Guo
Session: Poster session 04
1297P - An open-label, prospective phase II study of tislelizumab in combination with chidamide as consolidation therapy in locally advanced, unresectable, stage III NSCLC
Presenter: Yi Hu
Session: Poster session 04
1298P - Chemotherapy with concurrent proton vs. photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and immune therapy
Presenter: Francesco Cortiula
Session: Poster session 04
1299P - The role of radiotherapy in extensive-stage small cell lung cancer after durvalumab-based immunochemotherapy: A retrospective study
Presenter: Lingjuan Chen
Session: Poster session 04
1300P - Treatment and clinical outcome in recurrent/refractory locally advanced NSCLC following chemoradiotherapy and consolidative durvalumab
Presenter: Georg Evers
Session: Poster session 04